R&D companies are entering a paradigm shift. As we begin to leverage new technologies in AI, robotics, genetic sequencing, and low cost CRO’s, we will see early stage biotech/R&D start-ups  launch more efficiently and more affordably than ever before. Founders will retain more of their company and the path to proof of concepts will both dramatically quicken and cheapen, similar to how software and technology companies operate today. LabGarden hopes to be a platform  that can do its part to catalyze and catapult this new age of discovery for the next generation health startup.